Dr. Lara Discusses Epacadostat in Renal Cell Carcinoma

Primo N. Lara, MD
Published: Wednesday, Jul 19, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma (RCC).

Preliminary results from the phase II ECHO-202/KEYNOTE-037 trial showed encouraging response rates and safety signals with epacadostat plus pembrolizumab (Keytruda) in patients with metastatic RCC.

Lara says the advantages of a drug like epacadostat is that it is oral, so it provides an extra level of convenience, should it become a standard of care in the future.
 
SELECTED
LANGUAGE


Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma (RCC).

Preliminary results from the phase II ECHO-202/KEYNOTE-037 trial showed encouraging response rates and safety signals with epacadostat plus pembrolizumab (Keytruda) in patients with metastatic RCC.

Lara says the advantages of a drug like epacadostat is that it is oral, so it provides an extra level of convenience, should it become a standard of care in the future.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x